| 拓扑异构酶抑制剂治疗白血病的研究进展 |
| |
| 引用本文： | 张美荣,肖志坚.拓扑异构酶抑制剂治疗白血病的研究进展[J].白血病．淋巴瘤,2006,15(3):231-234. |
| |
| 作者姓名： | 张美荣 肖志坚 |
| |
| 作者单位： | 300020,天津,中国医学科学院中国协和医科大学血液学研究所血液病医院,实验血液学国家重点实验室;300020,天津,中国医学科学院中国协和医科大学血液学研究所血液病医院,实验血液学国家重点实验室 |
| |
| 摘 要： | DNA拓扑异构酶是参与细胞基本活动的重要核酶,其抑制剂主要通过形成"DNA-药物-酶"三聚复合物干扰DNA的复制发挥抗肿瘤作用。重点阐述以拓扑异构酶Ⅰ为靶点的新药在白血病治疗中应用现况、拓扑异构酶表达水平与临床疗效及预后的关系和白血病细胞对拓扑异构酶抑制剂产生耐药的发生机制等方面研究进展。
|
| 关 键 词： | 拓扑异构酶抑制剂 白血病 DNA复制 |
| 文章编号： | 1009-9921（2006）03-0231-04 |
| 收稿时间： | 2005-04-07 |
| 修稿时间： | 2005-12-25 |
Advances in the treatment of leukemia with topoisomerase inhibitors |
| |
| ZHANG Mei-rong,XIAO Zhi-jian.Advances in the treatment of leukemia with topoisomerase inhibitors[J].Journal of Leukemia & Lymphoma,2006,15(3):231-234. |
| |
| Authors: | ZHANG Mei-rong XIAO Zhi-jian |
| |
| Abstract: | DNA topoisomerases play an important role in the basic activity of cells. As anticancer drugs, topoisomerase inhibitors interfere with DNA duplication mainly by forming "DNA-drug-enzyme" compounds. Here we emphasized the progress of topoisomerase I inhibitors in the treatment of leukemia; the relation between DNA topoisomerase expression and therapeutic effect and prognosis; the cellular drug resistance mechanism of leukemia cells to topoisomerase inhibitors. |
| |
| Keywords: | Leukemia Topoisomerase inhibitors DNA duplication |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
| 点击此处可从《白血病．淋巴瘤》浏览原始摘要信息 |
| 点击此处可从《白血病．淋巴瘤》下载免费的PDF全文 |
